Skip to main content

Arctic Aurora LifeScience

Arctic Aurora LifeScience is an equity fund managed by Arctic in the Sektor – Helse category.

About this fund

Categorised as Sektor – Helse, Arctic Aurora LifeScience is an equity fund from Arctic.

Ulrica Slåne Bjerke has managed it since 2016, 10 years.

The fund dates from 2016, giving it 10 years of history.

It ranks 12 out of 18 in its peer group on return so far this year measured in NOK as of 13.11.2026.

Tracking error against its benchmark is 10.4%.

The manager-stated volatility is 18.5%.

Manager
Arctic
Category
Sektor – Helse
Region
Nordic
Sector
Health Care
Style
Sector Focus
SFDR
Article 8
ISIN
IE00BYQ7ZL84
Inception
2016-05-25
Benchmark
MSCI World Pharma / Biotech LifeScience
AUM
327 m NOK
Returns
YTD 4.7% · 1Y 9.9% · 3Y 7.7% · 5Y 7.4%

Portfolio managers

Actively managedEquityNordicHealth care
YTD Return · NOK
+4,7 %
10Y p.a.: 10y, annualised for class H Hedged · IE00BDHFW354 · NOK · institutional class as of 13.11.2026 7,5 %
NOK class A NOK
Last NAV 1 869,55 SEK · 13 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+4,7 %
YTD
+9,9 %
1y
+7,7 %
3y, annualised
+7,4 %
5y, annualised
Fund size
327,0 mill. NOK
Total fund AUM
Management fee
2,00 %
Annual · class A NOK · 0,80 %–2,00 % across 10 share classes
Ongoing charge
2,56 %
Annual · class A NOK
Performance fee
15%
of the excess return
Annual cost on platforms
1,76 %–2,06 %
Class A NOK · 7 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
May 2016
ISIN IE00BJRFW715
BenchmarkMSCI World Pharma / Biotech LifeScience
Fund website
Risk
Volatility (stated by the manager)17,4 %
Sharpe Ratio0,31
Info Ratio−0,64
Tracking Error9,2 %
About the fund
The fund

Arctic Aurora LifeScience is an actively managed global health care fund launched in 2016. It is managed by Arctic Asset Management, part of the Oslo-based Arctic Securities group. The company manages Norwegian and Nordic equity and fixed income funds aimed at institutions and wealthy investors.

Investment philosophy

The fund invests mainly in listed life science companies in Europe and the US that develop new treatments. The managers combine listed biotech companies with larger, profitable pharmaceutical companies in the US and Europe. Biotech is the core, and the large pharmaceutical companies are a supplement.

The managers

The fund is led by Ulrica Slåne Bjerke in Stockholm. She is chief investment officer for Arctic's health care funds and founded the fund, which she has managed since its start in 2016. She studied physiology and pharmacology at the Karolinska Institute and economics at the Stockholm School of Economics. Daniel Bolanowski, a partner in Stockholm, has been a life science analyst at Arctic since 2016 and has managed the fund since 2021. He holds master's degrees in molecular biotechnology and economics. Márk Fábián joined Arctic as a health care equity analyst in 2021 and has been associate portfolio manager since 2026. He has studied medicine, among other subjects. Torbjørn Bjerke, a physician by training and former chief executive of several pharmaceutical and life science companies, managed the fund from 2016 to 2023. Several of the managers have training in life sciences or medicine in addition to economics.

The portfolio

The fund has fluctuated more than comparable funds. The portfolio has a stable set of larger positions that combines large pharmaceutical companies such as AstraZeneca, Merck and Eli Lilly with biotech companies such as Argen-X, Bridgebio Pharma and Axsome Therapeutics.

FundTelligence description · 18/10/2026
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

Portfolio managers

UL
Lead Portfolio Manager
On the fund since May 27, 2016
DA
Portfolio Manager
On the fund since Jun 1, 2021

Position in the peer group

Sector Health Care Equities · 31 funds in the peer group. The number ranked and the date are stated per period. 12 of them converted to NOK.

7 of 18 funds ranked on a calculated return

#12/ 18Year to date
+4.72% NOK

as of 13 Nov 2026 · NOK class

About the figures

13 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#11/ 221 year
+9.92% NOK

as of 13 Nov 2026 · NOK class

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#11/ 223 years (ann.)
+7.74% NOK

as of 13 Nov 2026 · NOK class

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#9/ 225 years (ann.)
+7.39% NOK

as of 13 Nov 2026 · NOK class

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

Comparison basis

Year to date

Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

1 year

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

3 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

5 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.

Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.

About our data